Last reviewed 2026-05-22 · How we verify

AMPEROZIDE

Phase 2 active Small molecule ✓ Verified May 2026 Quality 31/100

AMPEROZIDE is a amperozide drug. It is currently in Phase 2 development.

Amperozide works by blocking an enzyme called fatty-acid amide hydrolase 1, which breaks down fatty acid amides in the brain.

Amperozide is a small molecule drug that targets fatty-acid amide hydrolase 1 (FAAH1), a key enzyme involved in the breakdown of fatty acid amides. It is classified as an amperozide, but its exact commercial status and approved indications are unknown. The mechanism of action of amperozide is not well-documented, but it is believed to work by inhibiting the activity of FAAH1, leading to increased levels of certain fatty acid amides in the brain. As a result, amperozide may have therapeutic effects on various conditions, although its specific uses and efficacy are not well-established. Further research is needed to fully understand the properties and potential applications of amperozide.

Likelihood of approval

15.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	AMPEROZIDE
Drug class	amperozide
Target	5-hydroxytryptamine receptor 6, Fatty-acid amide hydrolase 1
Modality	Small molecule
Therapeutic area	Metabolic
Phase	Phase 2

Mechanism of action

Think of fatty acid amides as a type of chemical messenger in the brain. By blocking the enzyme that breaks them down, amperozide allows these messengers to build up and have a greater effect on the brain. This can potentially lead to changes in mood, pain perception, and other brain functions.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

AMPEROZIDE CI brief — competitive landscape report
AMPEROZIDE updates RSS · CI watch RSS

Frequently asked questions about AMPEROZIDE

What is AMPEROZIDE?

AMPEROZIDE is a amperozide drug.

How does AMPEROZIDE work?

Amperozide works by blocking an enzyme called fatty-acid amide hydrolase 1, which breaks down fatty acid amides in the brain.

What drug class is AMPEROZIDE in?

AMPEROZIDE belongs to the amperozide class. See all amperozide drugs at /class/amperozide.

What development phase is AMPEROZIDE in?

AMPEROZIDE is in Phase 2.

What does AMPEROZIDE target?

AMPEROZIDE targets 5-hydroxytryptamine receptor 6, Fatty-acid amide hydrolase 1 and is a amperozide.

Drug class: All amperozide drugs
Target: All drugs targeting 5-hydroxytryptamine receptor 6, Fatty-acid amide hydrolase 1
Therapeutic area: All drugs in Metabolic

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing